drugset
drugset / Trial / NCT00787826

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

NCT00787826 ↗

Phase 2 Unknown 1000 enrolled U.S. Army Medical Research and Development Command
NaSingle-groupOpen-labelPrevention

Summary

This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine

Timeline

Start
2009-08-28
Primary completion
2019-11-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NDBR 101 Unknown 0.0025 ml Other

Indications

tularemia